• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

    2/12/24 4:14:06 PM ET
    $BIOS
    Blank Checks
    Finance
    Get the next $BIOS alert in real time by email
    SC 13G/A 1 ea193058-13ga2cantor_bioplus.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 2)*

     

    Under the Securities Exchange Act of 1934

     

    BioPlus Acquisition Corp.
    (Name of Issuer)
     
    Class A Ordinary Shares, par value $0.0001 per share
    (Titles of Class of Securities)
     
    G11217117
    (CUSIP Number)
     
    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☒Rule 13d-1(c)
    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 2 of 11

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Cantor Fitzgerald Securities

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New York

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     
    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 3 of 11

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Cantor Fitzgerald & Co.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New York

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     
    12

    TYPE OF REPORTING PERSON

    CO

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 4 of 11

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Cantor Fitzgerald, L.P.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     
    12

    TYPE OF REPORTING PERSON

    PN

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 5 of 11

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    CF Group Management, Inc.

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New York

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     
    12

    TYPE OF REPORTING PERSON

    CO

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 6 of 11

     

    1

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    Howard W. Lutnick

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

     
    12

    TYPE OF REPORTING PERSON

    IN

     

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 7 of 11

     

    Item 1(a). Name of Issuer:
       
      BioPlus Acquisition Corp.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
     

    260 MADISON AVENUE, SUITE 800, NEW YORK, NY, 10016

       
    Item 2(a). Name of Person Filing:
       
     

    Cantor Fitzgerald Securities, Cantor Fitzgerald Securities & Co., Cantor Fitzgerald, L.P., CF Group Management, Inc. and Howard W. Lutnick (collectively, the “Reporting Persons”).

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
     

    110 East 59th Street

    New York, New York 10022

     

    Item 2(c). Citizenship:
       
      Cantor Fitzgerald Securities is a general partnership formed in New York. Cantor Fitzgerald, L.P. is a Delaware limited partnership, CF Group Management, Inc. is a New York corporation and Mr. Lutnick is a citizen of the United States of America.
       
    Item 2(d). Titles of Classes of Securities:
       
      Class A Ordinary Shares, par value $0.0001 per share.
       
    Item 2(e). CUSIP Number:
       
      G11217117

     

    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

     

      (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
      (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) ☐ Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
      (f) ☐ Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
      (g) ☐ Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
      (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
      (j) ☐ Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).
      (k) ☐ Group in accordance with §240.13d-1(b)(1)(ii)(K).
         
      If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 8 of 11

     

    Item 4. Ownership
     

     

    The responses to Items 5-11 of the cover pages of this Schedule 13G are incorporated herein by reference.

     

    As of December 31, 2023, the Reporting Persons may be deemed to beneficially own an aggregate of no Class A Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”) of BioPlus Acquisition Corp. (the “Issuer”), representing 0.0% of the Issuer’s outstanding Common Stock.

     

    The percentage of the Common Stock held by the Reporting Persons is based on 13,617,477 Ordinary Shares outstanding as of August 14, 2023, as reported in the Issuer’s 10-Q filed with the Securities and Exchange Commission on August 14, 2023.

     

    Cantor Fitzgerald Securities (“CFS”) and Cantor Fitzgerald & Co. (“CF&CO”) were the record holders of the securities previously reported herein.

     

    CF Group Management, Inc. (“CFGM”) is the managing general partner of Cantor Fitzgerald, L.P. (“Cantor”) and directly or indirectly controls the managing general partner of CFS and CF&CO. Mr. Lutnick is Chairman and Chief Executive of CFGM and trustee of CFGM’s sole stockholder. Cantor, indirectly, holds a majority of the ownership interests of CFS. As such, each of Cantor, CFGM and Mr. Lutnick may be deemed to have beneficial ownership of the securities directly held by CFS and CF&CO. Each such entity or person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest they may have therein, directly, or indirectly.

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 9 of 11

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not Applicable.
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not Applicable.
       
    Item 10. Certification.

     

    By signing below the undersigned certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. G11217117 SCHEDULE 13G Page 10 of 11

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2024

     

      CANTOR FITZGERALD SECURITIES
       
      By: /s/ Howard W. Lutnick
        Name:  Howard W. Lutnick
        Title: Chief Executive Officer
       
      CANTOR FITZGERALD & CO.
       
      By: /s/ Howard W. Lutnick
        Name: Howard W. Lutnick
        Title: Chief Executive Officer
       
     

    CANTOR FITZGERALD, L.P.

       
      By: /s/ Howard W. Lutnick
        Name: Howard W. Lutnick
        Title: Chief Executive Officer
           
     

    CF GROUP MANAGEMENT, INC.

       
      By: /s/ Howard W. Lutnick
        Name: Howard W. Lutnick
        Title: Chief Executive Officer
       
      HOWARD W. LUTNICK
       
      By: /s/ Howard W. Lutnick
        Name: Howard W. Lutnick

     

    [Schedule 13G/A – BioPlus Acquisition Corp. – February 2024]

     

     

     

     

    CUSIP No. G01322109 SCHEDULE 13G Page 11 of 11

     

    Exhibit Index

     

    Exhibit No.   Description
    99.1   Joint Filing Agreement, dated as of February12, 2024, by and among the Reporting Persons

     

     

     

     

     

    Get the next $BIOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Bioplus Sponsor Llc

      4 - BioPlus Acquisition Corp. (0001856653) (Issuer)

      6/12/23 9:17:36 PM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate

      New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. ("BIOS" or the "Company") (NASDAQ:BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the "Business Combination Agreement"), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company's initial public offering ("Public Shares"). The Business Combination Agreement was dated as of May 2, 2023. The pa

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination

      EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. ("Avertix" or the "Company"), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation (dba BioPlus Acquisition Corp.) ("BIOS") (NASDAQ:BIOS), a special purpose acquisition company, announced today that the two companies have mutually agreed to terminate their proposed business combination. "While we were enthusiastic about the potential business combination with BIOS, we mutually agreed that the current market conditions are not co

      10/4/23 7:30:00 AM ET
      $BIOS
      Blank Checks
      Finance
    • Carbonhand is available for Veterans in the US

      Bioservo signs a Sales Agent agreement with Trivet Medical LLC for sales of Carbonhand to Hospitals, Clinics, and Medical Centers within the Veterans Health Administration and Department of Defense in the US. With the first Sales Agent in place, the grip-strengthening device Carbonhand is available for all US Veterans suffering from impaired hand function. KISTA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Trivet Medical LLC is a specialized strategic sales and distribution LLC, highly focused on commercializing disruptive, best-in-class med-tech devices and technologies. Founded by Charles Coyle, Trivet Medical's mission is to develop underrepresented and underserved healthcare conditions through

      8/29/23 3:03:00 AM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Financials

    Live finance-specific insights

    See more
    • Purple Innovation Announces Cooperative Framework with Coliseum Capital

      Company to Welcome New Directors to Board Adam Gray to Serve as Board Chair Gary DiCamillo to Continue to Serve as Lead Independent Director Company Will Redeem Cumulative Voting Proportional Representation Preferred Linked Stock Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No Pressure® Mattress," today announced that it has entered into a binding Memorandum of Understanding to establish a cooperative governance framework (the "Planned Cooperation Agreement") with Coliseum Capital Management, LLC (together with its managed funds and accounts, "Coliseum"), the largest stockholder of the Company o

      4/13/23 4:05:00 PM ET
      $ADES
      $BIOS
      $LAZY
      $LOGI
      Major Chemicals
      Industrials
      Blank Checks
      Finance

    $BIOS
    SEC Filings

    See more
    • SEC Form 15-12G filed by BioPlus Acquisition Corp.

      15-12G - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/16/23 4:15:07 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form 25-NSE filed by BioPlus Acquisition Corp.

      25-NSE - BioPlus Acquisition Corp. (0001856653) (Subject)

      10/6/23 4:03:10 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form RW filed by BioPlus Acquisition Corp.

      RW - BioPlus Acquisition Corp. (0001856653) (Filer)

      10/4/23 7:39:57 AM ET
      $BIOS
      Blank Checks
      Finance

    $BIOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/12/24 4:14:06 PM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/9/24 10:26:34 AM ET
      $BIOS
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by BioPlus Acquisition Corp. (Amendment)

      SC 13G/A - BioPlus Acquisition Corp. (0001856653) (Subject)

      2/7/24 2:00:23 PM ET
      $BIOS
      Blank Checks
      Finance